healthcare, regulatory and reimbursement landscape - morocco · pdf filesample reference code:...

SAMPLE

Reference Code: GDHC0028CHR

Publication Date: November 2012

Healthcare, Regulatory and Reimbursement Landscape

Morocco

SAMPLE

Healthcare, Regulatory and Reimbursement Landscape - Morocco

GDHC0028CHR / Published NOV 2012

© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form

Government Initiatives have Helped to Reduce the

Unemployment rate, which Augurs well for the Increasing

Working age Population in the Country; however,

Managing the Demands of the Increasing Elderly

Population is a Challenge for Healthcare Policy Makers in

Morocco

Age Groups, Morocco, Population Distribution (%), 2005 - 2020

Source: GlobalData; High Commission of Planning (Haut-commissariat au Plan, HCP), 2012a

*Estimated figure

The Implementation of Public Health Insurance Schemes,

Government Incentives for the Domestic Pharmaceutical

Manufacturers, Strong Patent Protection Laws and an

Increasing Elderly Population Provide the Moroccan

Healthcare Market with Significant Growth Potential;

however, the Limited Availability of Medicines in Public

Hospitals still Remains a Challenge

SAMPLE




Pharmaceutical Market ($m), Morocco, 2005 - 2020

Source: GlobalData; Morocco–US FTA, 2007

*Estimated figures

Government Incentives, Expanding the Coverage of Health

Insurance and Healthcare Reforms are Driving

Components of the Moroccan Healthcare System which

will Nullify the Effect of Barriers such as the High Poverty

rate

Improvements in the Moroccan Regulatory System became

a Significant Evolutionary Event in the History of the

Pharmaceutical Market in Morocco, Simplifying and

Expediting the Regulatory Processes Related to the

Pharmaceutical Industry

SAMPLE




Country Profile, Morocco, 2012

Country Profile

Parameter Sub-Parameters

Economic

EnvironmentStability

Government

Initiatives GDP Growth Employment

Healthcare

Market

Pharmaceutical

Market

Pharmaceutical

Market Growth

Medical Device

Market

Medical Device

Market Growth

Healthcare

Infrastructure

Government

Initiatives

Hospital Beds to

Population Ratio

Doctors to

Population Ratio

Environmental

Health

Healthcare

ExpenditureOverall Public Share Private Share

R&D

Expenditure

Political

EnvironmentPolitical Stability

Healthcare

Initiatives Economic Policy

DemographicsPopulation

Working Age

GroupElderly

Regulatory

Environment

Approval

Process Approval Time Government Initiatives

Reimbursement

Environment

AccessGovernment Initiatives

WeakStrong Moderate

Source: GlobalData Analysis

SAMPLE




1 Table of Contents

1 Table of Contents .................................................................................................................................. 5 1.1 List of Tables .................................................................................................................................. 7 1.2 List of Figures ................................................................................................................................. 8

2 Introduction ..........................................................................................................................................10 2.1 Report Guidance ............................................................................................................................10

3 Overview of the Pharmaceutical and Medical Devices Market .............................................................11 3.1 Pharmaceutical Market ..................................................................................................................11

3.1.1 Market Overview ...................................................................................................................11 3.1.2 Supply Channels ..................................................................................................................13 3.1.3 Market Segments .................................................................................................................15 3.1.4 Major Disease Areas ............................................................................................................17 3.1.5 Major Players ........................................................................................................................18

3.2 Medical Device Market ..................................................................................................................43 3.2.1 Market Overview ...................................................................................................................43

3.3 Market Drivers and Barriers ...........................................................................................................44 3.3.1 Drivers ..................................................................................................................................44 3.3.2 Barriers .................................................................................................................................45

4 Market Access ......................................................................................................................................47 4.1 Reimbursement and Payer Landscape ..........................................................................................47

4.1.1 Healthcare System Overview ...............................................................................................47 4.1.2 Reimbursement Process ......................................................................................................47 4.1.3 Overview of Insurance Providers ..........................................................................................48 4.1.4 Patient Share in Healthcare Spending ..................................................................................51 4.1.5 Price Trend in Healthcare Services ......................................................................................52 4.1.6 Pricing Policies .....................................................................................................................53

4.2 Regulatory Landscape ...................................................................................................................55 4.2.1 Overview of Regulatory Agencies .........................................................................................55 4.2.2 Drug Approval Process .........................................................................................................56 4.2.3 New Device Approval Process .............................................................................................58 4.2.4 Licensing Process for Pharmaceutical Establishments ........................................................58 4.2.5 Licensing Process for Exports and Imports ..........................................................................59 4.2.6 Intellectual Property Rights Landscape ................................................................................60 4.2.7 Clinical Trial Regulations ......................................................................................................64 4.2.8 Pharmaceutical Advertising Regulations ..............................................................................66 4.2.9 Pharmacy Regulations .........................................................................................................68 4.2.10 Labeling and Packing Regulations .......................................................................................69

5 Country Analysis ..................................................................................................................................70 5.1 Political Environment .....................................................................................................................70

5.1.1 Political Structure ..................................................................................................................70 5.1.2 Analysis of the Current Political Environment .......................................................................71 5.1.3 Healthcare Policy Initiatives ..................................................................................................72

5.2 Economic Landscape ....................................................................................................................75 5.3 Economic Indicators ......................................................................................................................77

5.3.1 Gross Domestic Product .......................................................................................................77 5.3.2 Gross National Income .........................................................................................................81 5.3.3 Inflation .................................................................................................................................82 5.3.4 Currency Exchange Rate......................................................................................................86 5.3.5 Foreign Direct Investment.....................................................................................................87 5.3.6 Foreign Exchange Reserves ................................................................................................88 5.3.7 Trade Balance ......................................................................................................................89 5.3.8 Government Structural Balance ............................................................................................91 5.3.9 Total Central Government Debt ............................................................................................93 5.3.10 Public External Debt .............................................................................................................94 5.3.11 Major Industries ....................................................................................................................95

5.4 Demographics................................................................................................................................96 5.4.1 Population .............................................................................................................................96 5.4.2 Education and Literacy .......................................................................................................111 5.4.3 Employment ........................................................................................................................113 5.4.4 Disease Burden ..................................................................................................................114

SAMPLE




5.5 Healthcare Infrastructure .............................................................................................................115 5.5.1 Healthcare Facilities ...........................................................................................................115 5.5.2 Healthcare Parameters .......................................................................................................120 5.5.3 Environmental Health .........................................................................................................122 5.5.4 Healthcare Personnel .........................................................................................................126

5.6 Healthcare Expenditure ...............................................................................................................128 5.6.1 Overview.............................................................................................................................128 5.6.2 Major Components of Healthcare Spending .......................................................................129 5.6.3 Share of Public and Private Sector .....................................................................................130

5.7 Trade Associations ......................................................................................................................131 5.7.1 Moroccan Pharmaceutical Industry Association .................................................................131 5.7.2 Morocco Health Innovation .................................................................................................131

5.8 Trade Fairs ..................................................................................................................................132 6 Opportunities and Challenges ............................................................................................................133

6.1 Opportunities ...............................................................................................................................133 6.2 Challenges ...................................................................................................................................134

7 Appendix ............................................................................................................................................136 7.1 Abbreviations ...............................................................................................................................136 7.2 Bibliography .................................................................................................................................138 7.3 Methodology ................................................................................................................................143

7.3.1 Coverage ............................................................................................................................143 7.3.2 Secondary Research ..........................................................................................................143 7.3.3 Forecasting .........................................................................................................................144 7.3.4 Primary Research ...............................................................................................................144 7.3.5 Expert Panel Validation ......................................................................................................144

7.4 Disclaimer ....................................................................................................................................144

SAMPLE




1.1 List of Tables

Table 1: Pharmaceutical Market ($m), Morocco, 2006 - 2011 ................................................................11 Table 2: Pharmaceutical Market ($m), Morocco, Forecast, 2012 - 2020* ...............................................12 Table 3: Generic Pharmaceutical Market, Revenue ($m), Morocco, 2006 - 2011 ..................................15 Table 4: Generic Pharmaceutical Market, Revenue ($m), Morocco, Forecast, 2012 - 2020 ..................16 Table 5: Major Products, Sanofi, Global, Revenue ($m), 2012 ...............................................................19 Table 6: Major Products, Sanofi-aventis Morocco, 2012 ........................................................................19 Table 7: Major Products, Maphar, 2012 ..................................................................................................20 Table 8: Late Stage Pipeline, Sanofi, 2012 .............................................................................................20 Table 9: Major Products, GlaxoSmithKline, Global, Revenue ($m), 2012 ..............................................24 Table 10: Late Stage Pipeline, GlaxoSmithKline, 2012 ............................................................................24 Table 11: Major Products, Pfizer, Global, Revenue ($m), 2012 ................................................................30 Table 12: Late Stage Pipeline, Pfizer, 2012 ..............................................................................................31 Table 13: Major Products, Sothema, 2012 ...............................................................................................36 Table 14: Major Products, Laprophan, 2012 .............................................................................................40 Table 15: Healthcare Spending, Morocco, Patient‟s Share (%), 2005 - 2010 ...........................................51 Table 16: Annual Price Change, Morocco, Healthcare Segments (%), 2007 - 2011 ................................53 Table 17: GDP Per Capita ($), Morocco, 2006 - 2011 ..............................................................................77 Table 18: GDP Per Capita ($), Morocco, Forecast, 2012 - 2020 ..............................................................78 Table 19: GDP, Morocco, Annual Growth (%), 2006 - 2011 .....................................................................79 Table 20: GDP, Morocco, Annual Growth (%), Forecast, 2012 - 2020 .....................................................80 Table 21: GNI Per Capita ($), Morocco, 2006 - 2011 ...............................................................................81 Table 22: Average Consumer Price Index, Morocco, 2006 - 2011 ...........................................................82 Table 23: Average Consumer Price Index, Morocco, Forecast, 2012 - 2020 ...........................................83 Table 24: Average Consumer Price, Morocco, Annual Change (%), 2006 - 2011 ....................................84 Table 25: Average Consumer Price, Morocco, Annual Change (%), 2012 - 2020 ....................................85 Table 26: Currency Exchange Rate (MAD/$), Morocco, 2006 - 2011 .......................................................86 Table 27: Foreign Direct Investment ($bn), Morocco, 2006 - 2011 ...........................................................87 Table 28: Foreign Exchange Reserves ($bn), Morocco, 2006 - 2011 .......................................................88 Table 29: Exports of Goods and Services ($bn), Morocco, 2006 - 2011 ..................................................89 Table 30: Imports of Goods and Services ($bn), Morocco, 2006 - 2011 ...................................................90 Table 31: General Government Structural Balance ($bn), Morocco, 2006 - 2011 ....................................91 Table 32: General Government Structural Balance ($bn), Morocco, Forecast, 2012 - 2020 ....................92 Table 33: Total Central Government Debt ($bn), Morocco, 2006 - 2011 ..................................................93 Table 34: Public External Debt ($bn), Morocco, 2006 - 2011 ...................................................................94 Table 35: Major Industries, Morocco, Production ($bn), 2009 ..................................................................95 Table 36: Population (million), Morocco, 2006 - 2011 ...............................................................................96 Table 37: Population (million), Morocco, Forecast, 2012 - 2020 ...............................................................97 Table 38: Urban and Rural Population, Morocco, Share (%), 2006 - 2011 ...............................................98 Table 39: Urban and Rural Population, Morocco, Share (%), Forecast, 2012 - 2020 ...............................99 Table 40: Age Groups, Population Distribution (%), Morocco, 2006 - 2011 ............................................100 Table 41: Age Groups, Population Distribution (%), Morocco, Forecast, 2012 - 2020 ............................101 Table 42: Births (Per 1,000 Population), Morocco, 2005 - 2010 .............................................................102 Table 43: Mortality (Per 1,000 Population), Morocco, 2005 - 2010 .........................................................103 Table 44: Major Causes of Mortality („000s), Morocco, 2008 ..................................................................104 Table 45: Children <5 Years Age, Morocco, Mortality Rate (Per 1000 Live Births), 2005 - 2010 ...........105 Table 46: Immunization („000s), Morocco, 2005-2010 ............................................................................106 Table 47: Major Causes of Male Mortality („000s), Morocco, 2008 .........................................................107 Table 48: Major Causes of Female Mortality („000s), Morocco, 2008 .....................................................108 Table 49: Gender Ratio (M/F), Morocco, 2006 - 2011 ............................................................................109 Table 50: Life Expectancy at Birth (Years), Morocco, 2006 - 2011 .........................................................110 Table 51: Levels of Education, Morocco, Gross Enrolment (%), 2010 ....................................................112 Table 52: Unemployment Rate (%), Morocco, 2006 - 2011 ....................................................................113 Table 53: Major Diseases, Morocco, DALY (Per 100,000 Population), 2004 .........................................114 Table 54: Number of Hospitals, Morocco, 2006 - 2011 ...........................................................................115 Table 55: Public and Private Hospitals, Morocco, 2006 - 2011 ..............................................................116 Table 56: Basic Public Urban - Rural Health Centers, Morocco, 2006 - 2011 ........................................117 Table 57: Dialysis Units in Hospitals (Per 100,000 Population), Morocco, 2006 - 2011 .........................118 Table 58: Diagnostic Services, Morocco, 2011 .......................................................................................119 Table 59: Hospital Beds (Per 100,000 Population), Morocco, 2006 - 2011 ............................................120 Table 60: Physicians (Per 100,000 Population), Morocco, 2006 - 2011 .................................................121 Table 61: CO2 Emissions (Million Tons), Morocco, 2005 - 2010 .............................................................122 Table 62: PM10 (Micrograms Per Cubic Meter), Morocco, 2005 - 2010 .................................................123

SAMPLE




Table 63: Organic Water Pollutant Emissions (Metric Tons per Day), Morocco, 2005-2010 ..................124 Table 64: Disposable Solid Waste, Share (%), Morocco, 2011 ..............................................................125 Table 65: Nurses (Per 100,000 Population), Morocco, 2006 - 2011 .......................................................127 Table 66: Dentists (Per 100,000 Population), Morocco, 2006 - 2011 .....................................................127 Table 67: Healthcare Expenditure (% of GDP), Morocco, 2006 - 2011 ..................................................128 Table 68: Public Healthcare Expenditure, Morocco, Share of Major Components (%), 2011 .................129 Table 69: Healthcare Expenditure, Morocco, Public-Private Share (%), 2006- 2011* ............................130 Table 70: Major Healthcare Trade Fairs, Morocco, 2012 ........................................................................132

1.2 List of Figures

Figure 1: Pharmaceutical Market ($m), Morocco, 2006 - 2011 ..................................................................11 Figure 2: Pharmaceutical Market ($m), Morocco, Forecast, 2012 - 2020* .................................................12 Figure 3: Distribution Channels, Morocco, Price Margins (%), 2007 ..........................................................14 Figure 4: Generic Pharmaceutical Market, Revenue ($m), Morocco, 2006 - 2011 ..................................15 Figure 5: Generic Pharmaceutical Market, Revenue ($m), Morocco, Forecast, 2012 - 2020.....................16 Figure 6: Drivers and Barriers, Healthcare Market, Morocco, 2012 ...........................................................46 Figure 7: Structure of the Healthcare Insurance System, Morocco, 2011 ................................................48 Figure 8: Healthcare Spending, Morocco, Patient‟s Share (%), 2005 - 2010 ...........................................51 Figure 9: Annual Price Change, Morocco, Healthcare Segments (%), 2007 - 2011 ..................................52 Figure 10: Pricing Procedure, Morocco, 2012 ............................................................................................54 Figure 11: New Drug Approval Process, Morocco, 2012 ...........................................................................57 Figure 12: Patent Approval Process, Morocco, 2012 .................................................................................61 Figure 13: Trademark Approval Process, Morocco, 2012 ..........................................................................63 Figure 14: Clinical Trial Approval Process, Morocco, 2012 ........................................................................65 Figure 15: Advertisement Approval Process, Morocco, 2012 ....................................................................67 Figure 16: GDP Per Capita ($), Morocco, 2006 - 2011 ..............................................................................77 Figure 17: GDP Per Capita ($), Morocco, Forecast, 2012 - 2020 ..............................................................78 Figure 18: GDP, Morocco, Annual Growth (%), 2006 - 2011 .....................................................................79 Figure 19: GDP, Morocco, Annual Growth (%), Forecast, 2012 - 2020 .....................................................80 Figure 20: GNI Per Capita ($), Morocco, 2006 - 2011 ...............................................................................81 Figure 21: Average Consumer Price Index, Morocco, 2006 - 2011 ...........................................................82 Figure 22: Average Consumer Price Index, Morocco, Forecast, 2012 - 2020 ............................................83 Figure 23: Average Consumer Price, Morocco, Annual Change (%), 2006 - 2011 ....................................84 Figure 24: Average Consumer Price, Morocco, Annual Change (%), 2012 - 2020 ....................................85 Figure 25: Currency Exchange Rate (MAD/$), Morocco, 2006 - 2011 .......................................................86 Figure 26: Foreign Direct Investment ($bn), Morocco, 2006 - 2011 ...........................................................87 Figure 27: Foreign Exchange Reserves ($bn), Morocco, 2006 - 2011 .......................................................88 Figure 28: Exports of Goods and Services ($bn), Morocco, 2006 - 2011 ..................................................89 Figure 29: Imports of Goods and Services ($bn), Morocco, 2006 - 2011 ...................................................90 Figure 30: General Government Structural Balance ($bn), Morocco, 2006 - 2011 ....................................91 Figure 31: General Government Structural Balance ($bn), Morocco, Forecast, 2012 - 2020 ....................92 Figure 32: Total Central Government Debt ($bn), Morocco, 2006 - 2011 ..................................................93 Figure 33: Public External Debt ($bn), Morocco, 2006 - 2011 ...................................................................94 Figure 34: Major Industries, Morocco, Production ($bn), 2009 ..................................................................95 Figure 35: Population (million), Morocco, 2006 - 2011 ...............................................................................96 Figure 36: Population (million), Morocco, Forecast, 2012 - 2020 ...............................................................97 Figure 37: Urban and Rural Population, Morocco, Share (%), 2006 - 2011 ...............................................98 Figure 38: Urban and Rural Population, Morocco, Share (%), Forecast, 2012 - 2020 ...............................99 Figure 39: Age Groups, Population Distribution (%), Morocco, 2006 - 2011 ............................................100 Figure 40: Age Groups, Population Distribution (%), Morocco, Forecast, 2012 - 2020 ............................101 Figure 41: Births (Per 1,000 Population), Morocco, 2005 - 2010 .............................................................102 Figure 42: Mortality (Per 1,000 Population), Morocco, 2005 - 2010 .........................................................103 Figure 43: Major Causes of Mortality („000s), Morocco, 2008 ..................................................................104 Figure 44: Children <5 Years Age, Morocco, Mortality Rate (Per 1000 Live Births), 2005 - 2010 ...........105 Figure 45: Immunization („000s), Morocco, 2005-2010 ............................................................................106 Figure 46: Major Causes of Male Mortality („000s), Morocco, 2008 .........................................................107 Figure 47: Major Causes of Female Mortality („000s), Morocco, 2008 .....................................................108 Figure 48: Gender Ratio (M/F), Morocco, 2006 - 2011 ............................................................................109 Figure 49: Life Expectancy at Birth (Years), Morocco, 2006 - 2011 .........................................................110 Figure 50: Levels of Education, Morocco, Gross Enrolment (%), 2010 ....................................................112 Figure 51: Unemployment Rate (%), Morocco, 2006 - 2011 ....................................................................113 Figure 52: Major Diseases, Morocco, DALY (Per 100,000 Population), 2004 ..........................................114

SAMPLE




Figure 53: Number of Hospitals, Morocco, 2006 - 2011 ...........................................................................115 Figure 54: Public and Private Hospitals, Morocco, 2006 - 2011 ...............................................................116 Figure 55: Basic Public Urban - Rural Health Centers, Morocco, 2006 - 2011 ........................................117 Figure 56: Dialysis Units in Hospitals (Per 100,000 Population), Morocco, 2006 - 2011 .........................118 Figure 57: Diagnostic Services, Morocco, 2011 .......................................................................................119 Figure 58: Hospital Beds (Per 100,000 Population), Morocco, 2006 - 2011 ............................................120 Figure 59: Physicians (Per 100,000 Population), Morocco, 2006 - 2011 .................................................121 Figure 60: CO2 Emissions (Million Tons), Morocco, 2005 - 2010 .............................................................122 Figure 61: PM10 (Micrograms Per Cubic Meter), Morocco, 2005 - 2010 .................................................123 Figure 62: Organic Water Pollutant Emissions (Metric Tons per Day), Morocco, 2005 - 2010 ................124 Figure 63: Disposable Solid Waste, Share (%), Morocco, 2011 ..............................................................125 Figure 64: Nurses (Per 100,000 Population), Morocco, 2006 - 2011 .......................................................126 Figure 65: Dentists (Per 100,000 Population), Morocco, 2006 - 2011 .....................................................127 Figure 66: Healthcare Expenditure (% of GDP), Morocco, 2006 - 2011 ..................................................128 Figure 67: Public Healthcare Expenditure, Morocco, Share of Major Components (%), 2011 .................129 Figure 68: Healthcare Expenditure, Morocco, Public-Private Share (%), 2006 – 2011* ..........................130 Figure 69: Opportunities and Challenges, Healthcare Market, Morocco, 2012 ........................................135

SAMPLE




2 Introduction

2.1 Report Guidance

The report begins with an “Executive Summary”, which gives an overview of the healthcare market in

Morocco and the key factors driving the market there. The Executive Summary also provides a

snapshot of the demographic, regulatory and reimbursement landscape, as well as the healthcare

infrastructure of Morocco.

The “Overview of the Pharmaceutical and Medical Devices Market” chapter provides an overview of

the pharmaceutical and medical device market in Morocco, including the market size, market

segmentation by generics, Over-the-Counter (OTC) and biologics/biosimilar products, and the key

drivers and barriers for the market. The section also includes profiles of the major players, including a

SWOT assessment.

The “Market Access” chapter covers the reimbursement and payer landscape, as well as the

regulatory landscape. The reimbursement and payer landscape elaborates on the features of the

healthcare reimbursement process for Morocco. It includes details of the reimbursement process, the

insurance providers, pricing policies and drug price trends in the country. The regulatory landscape

section provides an overview of the regulatory agencies and approval processes for new drugs and

medical devices. The licensing process for the manufacturing and export/import of pharmaceuticals,

the regulations for pharmaceutical advertising, labeling, packaging, clinical trials and an overview of

the landscape for intellectual property rights are also covered in this chapter.

The “Country Analysis” chapter provides a detailed analysis of the political and economic

environment of Morocco. It analyzes the economic indicators, demographics, healthcare

infrastructure and healthcare expenditure of Morocco.

The “Opportunities and Challenges” chapter provides an overview of the opportunities and

challenges for growth that exist in the healthcare market of Morocco.

SAMPLE




3 Overview of the Pharmaceutical and Medical Devices Market

3.1 Pharmaceutical Market

3.1.1 Market Overview

Figure 1: Pharmaceutical Market ($m), Morocco, 2006 - 2011

Source: GlobalData; Morocco - US FTA, 2007

*Estimated figures

Table 1: Pharmaceutical Market ($m), Morocco, 2006 - 2011

Year 2006 2007 2008 2009 2010 2011*

Revenue


*Estimated figures

SAMPLE




Figure 2: Pharmaceutical Market ($m), Morocco, Forecast, 2012 - 2020*


*Estimated figures

Table 2: Pharmaceutical Market ($m), Morocco, Forecast, 2012 - 2020*

Year 2012 2013 2014 2015 2016 2017 2018 2019 2020

Revenue


*Estimated figures

SAMPLE


GDHC0028CHR / Published NOV 2012 6


7 Appendix

7.1 Abbreviations

ACEI : Angiotensin Converting Enzyme Inhibitors

ADA : Agence pour le Développement Agricole (Agency for Agricultural Development)

AMIP : Association Marocaine de Industrie Pharmaceutique (Moroccan Association of the

Pharmaceutical Industry)

AMO : l’Assurance Maladie Obligatoire (Mandatory Health Insurance)

ANAM : Agence Nationale de l'Assurance Maladie (National Agency of Health

Association of the Pharmaceutical Industry)

BCG : Bacillus Calmette-Guerin

bn : Billion

BOD : Biochemical Oxygen Demand

CAGR : Compound Annual Growth Rate

CCB : Calcium Channel Blocker

CNOPS : Caisse Nationale des Organismes de Prévoyance Sociale (National Fund

for Social Welfare Organizations)

CNSS : Caisse Nationale de Sécurité Sociale (National Social Security Fund)

CPI : Consumer Price Index

CVS : Cardiovascular System

DAENF : Department of Literacy and Non-Formal Education

DALY : Disability Adjusted Life Years

DPRF : Directeur de la Planification et des Ressources Financières

(Director of Planning and Financial Resources)

DTCP : Diphtherie, Tetanus, Pertussis and Poliomeylite

ESSB : Etablissements de soins de santé de base

(Basic health care establishments)

FDA : Food and Drug Administration

FDI : Foreign Direct Investment

FTA : Free Trade Agreement

GDP : Gross Domestic Product

GI : Gastrointestinal

GNI : Gross National Income

HCP : High Commission of Planning

IFPMA : International Federation of Pharmaceutical Manufacturers and Associations

IMCI : Integrated Management of Child Illness

IMF : International Monetary Fund

SAMPLE


GDHC0028CHR / Published NOV 2012 Page 137


INAS : Institute National d'Administration de Santé

(National Institute of Health Insurance)

KACST : King Abdulaziz City for Science and Technology

m : million

MoH : Ministry of Health

MRP : Maximum Retail Price

OECD : Organization for Economic Co-operation and Development

OPP : Out of Pocket Payment

OTC : Over the Counter

R&D : Research and Development

RAMED : Regime d’Assistance Medicale (Medical Assistance Program)

TRIPS : Trade-Related Aspects of Intellectual Property Rights

UAE : United Arab Emirates

UK : United Kingdom

UNCTAD: UN Conference on Trade and Development

UNICEF : The UN Children‟s Fund

US FTA : United States Free Trade Agreement

WEO : World Economic Outlook

WHO : World Health Organization

WIPO : World Intellectual Property Organization

WTO : World Trade Organization

SAMPLE




7.2 Bibliography

Agency for Agricultural Development (Agence pour le Développement Agricole, ADA) (2009).

Investor's Guide. ADA. Available from:

http://www.ada.gov.ma/en/incitations_a_linvestissement/guide_de_l_investisseur_agence_develope

ment_agricole_plan_maroc_vert.php. [Accessed May 29, 2012].

Agency for the Promotion and Development of the North (2009). Medical Infrastructure. Available

from:

http://www.apdn.ma/index.php?option=com_content&view=article&id=304&Itemid=290&lang=en.

[Accessed May 22, 2012].

ANAM (2012a). Equipment and Medical Devices. Available from:

http://www.assurancemaladie.ma/anam.php?id_espace=6&id_srub=102. [Accessed May 28, 2012].

ANAM (2012b). RAMED. Available from: http://www.anam.ma/anam.php?id_espace=4&id_rub=4.

[Accessed June 21, 2012].

ANAM (2012c). Employer. Available from: http://www.anam.ma/anam.php?id_espace=6&id_srub=19.


ANAM (2012d). AMO. Available from: http://www.anam.ma/anam.php?id_espace=4&id_rub=3.


ANAM (2012e). Medication Guide. Available from:

http://www.assurancemaladie.ma/anam.php?id_espace=6&id_srub=19. [Accessed June 22, 2012].

Ball D (2011). Pharmaceutical Pricing Policies and Interventions. WHO and Health Action

International (2011). Available from: http://www.haiweb.org/medicineprices/05062011/Mark-

ups%20final%20May2011.pdf.

Benhassine B and Harrami N (2012). Morocco, Mobility of Health Professionals. International

Organization for Migration. Available from:

http://www.mohprof.eu/LIVE/DATA/National_reports/national_report_Morocco.pdf.

Benyahia N (2009). Morocco-Healthcare. UK Trade and Investment. Association of British Healthcare

Industries. Overview of Medical Device Market. Available from:

http://www.google.co.in/url?sa=t&rct=j&q=90%25%20of%20morocco%E2%80%99s%20medical%20

supplies%20%20morocco&source=web&cd=1&ved=0CFQQFjAA&url=http%3A%2F%2Fwww.abhi.or

g.uk%2Fmultimedia%2Fe-

newswire%2Fissue76%2Fmorocco.doc&ei=WpvyT7DPOcbLrQf2qZi0CQ&usg=AFQjCNE_Xg4CZ0v-

s6w_K4j1NyjaHwnnWg. [Accessed May 28, 2012].

Bergh SI (2006). MENA Region Case-Study: Morocco. Presentation at Globalisation and Economic

Success: Policy Options for Africa, Cairo. Available from:

http://www.eip.gov.eg/Upload/ConferenceDocs/321/GlobalizationConferancePapers.pdf.

Berrada EAG et al (2012). Trends in Antihypertensives Use Among Moroccan Patients.

Pharmacoepidemiology and Drug Safety.21(10):1067-73..

Catusse M et al (2007). Decentralization and its Paradoxes in Morocco. HAL open archive. Halshs-

00355114, version 1 - 22 Jan 2009.

Centre De Documentation En Santé (2012). Number of Hospitals. Available from:

http://www.sante.gov.ma/inas/inas.htm ICDS - iNAS. [Accessed May 24, 2012].

Chin R and Bairu M (2011). Clinical Trial Regulations, Morocco. Global Clinical Trials, UK. Available

from: http://www.ibs.it/libro+inglese/global-clinical-trials/9780123815378.html. [Accessed May 25,

2012].

Eventseye (2012). Trade Fairs. Available Ffrom: http://www.eventseye.com/fairs/c1_trade-

shows_morocco.html. [Accessed mMay 24, 2012].

HCP (2012a). Population. Projections of the population by age group and sex (thousands and mid):

1960-2050. Available from: http://www.hcp.ma/Projections-de-la-population-totale-par-groupe-d-age-

et-sexe-en-milliers-et-au-milieu-de-l-annee-1960-2050_a676.html. [Accessed, 2012].

http://www.ada.gov.ma/en/incitations_a_linvestissement/guide_de_l_investisseur_agence_developement_agricole_plan_maroc_vert.php

http://www.ada.gov.ma/en/incitations_a_linvestissement/guide_de_l_investisseur_agence_developement_agricole_plan_maroc_vert.php

http://www.apdn.ma/index.php?option=com_content&view=article&id=304&Itemid=290&lang=en

http://www.assurancemaladie.ma/anam.php?id_espace=6&id_srub=102

http://www.anam.ma/anam.php?id_espace=4&id_rub=4

http://www.anam.ma/anam.php?id_espace=4&id_rub=3

http://www.assurancemaladie.ma/anam.php?id_espace=6&id_srub=19

http://www.haiweb.org/medicineprices/05062011/Mark-ups%20final%20May2011.pdf

http://www.haiweb.org/medicineprices/05062011/Mark-ups%20final%20May2011.pdf

http://www.mohprof.eu/LIVE/DATA/National_reports/national_report_Morocco.pdf

http://www.google.co.in/url?sa=t&rct=j&q=90%25%20of%20morocco%E2%80%99s%20medical%20supplies%20%20morocco&source=web&cd=1&ved=0CFQQFjAA&url=http%3A%2F%2Fwww.abhi.org.uk%2Fmultimedia%2Fe-newswire%2Fissue76%2Fmorocco.doc&ei=WpvyT7DPOcbLrQf2qZi0CQ&usg=AFQjCNE_Xg4CZ0v-s6w_K4j1NyjaHwnnWg





http://www.hcp.ma/Projections-de-la-population-totale-par-groupe-d-age-et-sexe-en-milliers-et-au-milieu-de-l-annee-1960-2050_a676.html

http://www.hcp.ma/Projections-de-la-population-totale-par-groupe-d-age-et-sexe-en-milliers-et-au-milieu-de-l-annee-1960-2050_a676.html

SAMPLE




HCP (2012b). Unemployment Rate. Available from: http://www.hcp.ma/Emploi-chomage-

activite_r123.html. [Accessed May 21, 2012].

HCP (2012c). Annual CPI by sections for health division (Base 100: 2006). Available from:

http://www.hcp.ma/Sante_a216.html. [Accessed June 26, 2012].

HCP (2012d). Urbanization. Available from: http://www.hcp.ma/Enquetes_r10.html. [Accessed June

26, 2012].

HCP (2012e). The Price Index for 2011. Available from: http://www.hcp.ma/. [Accessed June 26,

2012].

Hikma Pharmaceuticals (2011). Pricing policy. Available from: http://hikma-

acquisition.production.investis.com/~/media/Files/H/Hikma-

Acquisition/Attachments/disclosures/prospectus-eng.pdf.

Honsali IE (2012). Agricultural Biotechnology Annual (2012). USDA Foreign Agricultural Service.

Available from:

http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual_

Rabat_Morocco_7-6-2012.pdf.

IEA (2012). Waste management. Available from:

http://www.un.org/esa/dsd/susdevtopics/sdt_pdfs/meetings2010/icm0310/1c_Samir_Bensaid.pdf.

IMF (2012). World Economic Outlook 2012. Available from:

http://www.imf.org/external/pubs/ft/weo/2012/01/weodata/weorept.aspx?sy=2005&ey=2017&scsm=1

&ssd=1&sort=country&ds=.&br=1&pr1.x=29&pr1.y=9&c=686&s=NGDP_R%2CNGDP_RPCH%2CN

GDP%2CNGDPD%2CNGDP_D%2CNGDPRPC%2CNGDPPC%2CNGDPDPC%2CPPPGDP%2CP

PPPC%2CPPPSH%2CPPPEX%2CNID_NGDP%2CNGSD_NGDP%2CPCPI%2CPCPIPCH%2CPC

PIE%2CPCPIEPCH%2CTM_RPCH%2CTMG_RPCH%2CTX_RPCH%2CTXG_RPCH%2CTXGO%2

CTMGO%2CLUR%2CLP%2CGGR%2CGGR_NGDP%2CGGX%2CGGX_NGDP%2CGGXCNL%2C

GGXCNL_NGDP%2CGGSB%2CGGXONLB%2CGGXONLB_NGDP%2CGGXWDN%2CGGXWDN_

NGDP%2CGGXWDG%2CGGXWDG_NGDP%2CNGDP_FY%2CBCA%2CBCA_NGDPD&grp=0&a=.

[Accessed April 2, 2012].

KACST (2012). History of Industrial Property in Saudi Arabia. King Abdulaziz City for Science and

Technology. Available from: http://www.kacst.edu.sa/en/innovation/patents/pages/about.aspx.

[Accessed on August 2, 2012].

Kettani A and Kettani N (2008). Pharmaceutical Advertising 2008. Pharmaceutical Advertising

Regulations. Global Legal Group, UK. Chapter 35. Available from: www.iclg.co.uk

Ministry of Economy and Finance (2012a). Gender Budget Report. Available from:

http://www.finances.gov.ma/depf/dpeg_action/genre/rapports/2012/genre_12_en.pdf.

Ministry of Economy and Finance (2012b). Ministry of Economy and Finance and EU Commission in

Morocco Organize a Workshop on Direct Public Aid. Available from:

http://www.finances.gov.ma/portal/page?_pageid=93,17858042&_dad=portal&_schema=PORTAL&id

=288&lang=En. [Accessed May 31, 2012].

Ministry of Economy and Finance (2012c). Gross National Disposable Income. Available from:

http://www.finances.gov.ma/portal/page?_pageid=93,17862107&_dad=portal&_schema=PORTAL


Ministry of Economy and Finance (2012d). Public Debt. Available from:

http://www.finances.gov.ma/portal/page?_pageid=93,17946058&_dad=portal&_schema=PORTAL.


Ministry of Economy and Finance (2012e). Major Industries. Available from:

http://www.finances.gov.ma/portal/page?_pageid=93,17862108&_dad=portal&_schema=PORTAL.


Ministry of Industry, Trade and New Technologies (2012). Trade Policies and Practices by Measure.

Licensing Process for Exports and Imports. Ministry of Industry, Trade and New Technologies (2012).

Available from:

http://www.google.co.in/url?sa=t&rct=j&q=ministry+of+industry+trade+and+new+technologies+moroc

http://www.hcp.ma/Emploi-chomage-activite_r123.html

http://www.hcp.ma/Emploi-chomage-activite_r123.html

http://www.hcp.ma/Sante_a216.html

http://www.hcp.ma/Enquetes_r10.html

http://hikma-acquisition.production.investis.com/~/media/Files/H/Hikma-Acquisition/Attachments/disclosures/prospectus-eng.pdf



http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual_Rabat_Morocco_7-6-2012.pdf

http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Agricultural%20Biotechnology%20Annual_Rabat_Morocco_7-6-2012.pdf

http://www.finances.gov.ma/depf/dpeg_action/genre/rapports/2012/genre_12_en.pdf

http://www.finances.gov.ma/portal/page?_pageid=93,17858042&_dad=portal&_schema=PORTAL&id=288?=En

http://www.finances.gov.ma/portal/page?_pageid=93,17858042&_dad=portal&_schema=PORTAL&id=288?=En



http://www.google.co.in/url?sa=t&rct=j&q=ministry+of+industry+trade+and+new+technologies+morocco+import+Import+procedure+for+pharmaceutical+products&source=web&cd=1&ved=0CEgQFjAA&url=http%3A%2F%2Fwww.wto.org%2Fenglish%2Ftratop_e%2Ftpr_e%2Fs217-03_e.doc&ei=daQ1UMiTCMWOrgeHxoHgDw&usg=AFQjCNHe0eeROOcrGlXvGQyLS8baPBd-lw&cad=rja

SAMPLE




co+import+Import+procedure+for+pharmaceutical+products&source=web&cd=1&ved=0CEgQFjAA&

url=http%3A%2F%2Fwww.wto.org%2Fenglish%2Ftratop_e%2Ftpr_e%2Fs217-

03_e.doc&ei=daQ1UMiTCMWOrgeHxoHgDw&usg=AFQjCNHe0eeROOcrGlXvGQyLS8baPBd-

lw&cad=rja. [Accessed June 18, 2012].

MoH (2006a). Summary Heavy Equipment Available Depending on the Areas of Health (March-

2006). Available from:

http://www.sante.gov.ma/Departements/DPRF/OffreSoinsMars2006/OffreSoins.htm. [Accessed May

24, 2012].

MoH (2006b). Health and Social Insurance (2006). Available from:

http://www.apdn.ma/images/stories/file/statis_sectorielles/Sante.pdf.

MoH (2006c). Code of Drug and Pharmacy. Available from:

http://srvweb.sante.gov.ma/Reglementation/ProfSante/Documents/17-04.pdf.

MoH (2007a). Distribution of beds in public hospitals by hospital type, by region and by province and

prefecture (June-2007). Available from:

http://www.sante.gov.ma/Departements/DPRF/OffreSoinsJuin07/OffreSoins.htm. [Accessed May 28,

2012].

MoH (2007b). Public and private health infrastructure by province and prefecture (June - 2007).

Available from:

http://www.sante.gov.ma/Departements/DPRF/OffreSoinsJuin07/FichiesPDF/TableauxRecapitulatifs/

EffectifsGlobaux/Infrastructures/2InfrastructurePublicPrivve.pdf.

MoH (2008). Health Action Plan, 2008-2012. MoH (2008). Overview of Pharmaceutical Market.

Available from: http://www.sante.gov.ma/INAS/pdf/Plan-action-08-12.pdf.

MoH (2012a) via Doctinews. Medical Device. Available from:

http://www.doctinews.com/actualites/1937--dispositifs-

medicaux&usg=ALkJrhgu0hMC84gMrcweNt35j2dMCf9IwA. [Accessed July 30, 2012].

MoH (2012b). Studies and Surveys. Available from:

http://srvweb.sante.gov.ma/Publications/Etudes_enquete/Pages/default.aspx. [Accessed March 26,

2012].

MoH (2012c). Regulatory Landscape. Available from: http://www.sante.gov.ma/. [Accessed May 24,

2012].

MoH (2012d). Overview of Regulatory Agency.

http://srvweb.sante.gov.ma/Reglementation/MedPharma/Pages/default.aspx. [Accessed May 24,

2012].

MoH (2012e). Drug Approval Process. MoH (2012). Available from:

http://www.sante.gov.ma/Departements/DMP/lncm/circuitsmedic.htm. [Accessed June 14, 2012].

MoH (2012f). Heavy biomedical equipment in existing public health facilities - 2011. Available from:

http://cartesanitaire.sante.gov.ma/offresoins/national.aspx. [Accessed May 25, 2012].

MoH (2012g). Gender Ratio. Available from: http://www.hcp.ma/downloads/. [Accessed March 27,

2012].

MoH (2012h). Study of Medical and Paramedical Demographics for 2025.

http://srvweb.sante.gov.ma/laDemographieMedicale/default.aspx. [Accessed May 25, 2012].

MoH (2012i). Opportunities. Available from:

http://srvweb.sante.gov.ma/Pages/actualites.aspx?IDActu=0. [Accessed May 25, 2012].

MoH, UAE (2012). Patent procedure. Available from:

http://www.farahatco.com/downloads/IP_Brochure.pdf.

Moroccan Agency for Investment Development (2012). Why Morocco. Available from:

http://www.invest.gov.ma/?lang=fr&Id=3. [Accessed June 14, 2012].

Morocco-USAFTAMorocco - US FTA (2007). Morocco Trade and Investment Guide. Available from:

http://www.moroccousafta.com/downloads/TIG07p3i-lPharmInfraFranchCinMajProj.pdf.

http://www.sante.gov.ma/Departements/DPRF/OffreSoinsMars2006/OffreSoins.htm

http://www.apdn.ma/images/stories/file/statis_sectorielles/Sante.pdf

http://www.sante.gov.ma/Departements/DPRF/OffreSoinsJuin07/OffreSoins.htm

http://www.sante.gov.ma/Departements/DPRF/OffreSoinsJuin07/FichiesPDF/TableauxRecapitulatifs/EffectifsGlobaux/Infrastructures/2InfrastructurePublicPrivve.pdf

http://www.sante.gov.ma/Departements/DPRF/OffreSoinsJuin07/FichiesPDF/TableauxRecapitulatifs/EffectifsGlobaux/Infrastructures/2InfrastructurePublicPrivve.pdf

http://www.sante.gov.ma/INAS/pdf/Plan-action-08-12.pdf

http://srvweb.sante.gov.ma/Publications/Etudes_enquete/Pages/default.aspx

http://www.sante.gov.ma/Departements/DMP/lncm/circuitsmedic.htm

http://cartesanitaire.sante.gov.ma/offresoins/national.aspx

http://www.moroccousafta.com/downloads/TIG07p3i-lPharmInfraFranchCinMajProj.pdf

SAMPLE




Morocco-USAFTAMorocco - US FTA (2012). Executive Summary of the Country Commercial Guide

for Morocco. Morocco-USAFTAMorocco - US FTA. Available from:

http://www.moroccousafta.com/maratglance.htm. [Accessed May 29, 2012].

OANDA (2012). Historical Exchange Rate. OANDA. Available from:

http://www.oanda.com/currency/historical-rates/. [Accessed, 2012].

OMPIC (2012a). How to file a patent. Patent. Office Marocain de la Propriété Industrielle et

Commerciale (2012). Available from: http://www.ompic.org.ma/ompic_en_191.shtm. [Accessed June

21, 2012].

OMPIC (2012b). How to register a trademark. Trademark. Office Marocain de la Propriété Industrielle

et Commerciale (2012). Available from: http://www.ompic.org.ma/ompic_en_186.shtm. [Accessed

June 21, 2012].

Parliamentary Committee offor Drugs (2011) via LesEcho. Pharmaceutical industry: Dangerous

Concentration. Available from:

http://lesechos.ma/index.php?option=com_content&view=article&id=12360:industrie-

pharmaceutique-dangereuse-concentration&catid=3:evenements. [Accessed May 22, 2012].

RAMED (2012). Executive summary. RAMED. Available from:

http://www.ramed.ma/ServicesEnligne/APropos.html. [Accessed May 25, 2012].

Sadiqi F (2008). Facing Challenges and Pioneering Feminist and Gender Studies: Women in Post-

colonial and Today‟s Maghrib*. African and Asian Studies 7 (2008) 447-470.

Semlali H (2010). The Morocco Country Case Study: Positive Practice Environments. WHO (2010).

Available from: http://www.who.int/workforcealliance/knowledge/PPEMorocco.pdf.

The Government of Morocco (2011). Literacy rate. Via Yacout Info. Available from:

http://www.yacout.info/Morocco-illiteracy-rate-reduction-to-32_a3650.html. [Accessed June 14, 2012].

The Government of Morocco (2012). Analysis of the current political environment. Via Morocco World

News. Available from: http://www.moroccoworldnews.com/2012/01/21564/king-mohammed-vi-

appoints-new-government/. [Accessed June 14, 2012].

The World Bank (2009). Corporate tax. Via Moroccan Agency for Investment Development (2012).

Available from: http://www.invest.gov.ma/?lang=fr&Id=3. [Accessed June 14, 2012].

The World Bank (2012a). Poverty Rate (% of population) Executive Summary. The World Bank.

Available from: http://data.worldbank.org/indicator/SI.POV.NAHC/countries/MA?display=graph.


The World Bank (2012b). Patient Share in Healthcare Spending. Out-of-pocket health expenditure (%

of total expenditure on health). Available from:

http://data.worldbank.org/indicator/SH.XPD.OOPC.TO.ZS?page=1. [Accessed June 12, 2012].

The World Bank (2012c). Gross Domestic Product. The World Bank. Available from:

http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. [Accessed May 3, 2012].

The World Bank (2012d). Gross National Income. The World Bank. Available from:

http://data.worldbank.org/indicator/NY.GNP.PCAP.CD. [Accessed May 1, 2012].

The World Bank (2012e). Foreign Direct Investment. The World Bank. Available from:

http://data.worldbank.org/indicator/BX.KLT.DINV.CD.WD/countries?page=1. [Accessed May 2, 2012].

The World Bank (2012f). Foreign Exchange Reserves. The World Bank. Available from: [Accessed

May 2, 2012].

The World Bank (2012g). Exports of goods and services. The World Bank. Available from:

http://data.worldbank.org/indicator/NE.EXP.GNFS.ZS. [Accessed May 8, 2012].

The World Bank (2012h). Imports of goods and services. The World Bank. Available from:

http://data.worldbank.org/indicator/NE.IMP.GNFS.ZS. [Accessed May 8, 2012].

The World Bank (2012i). Children <5 Years Age, Mortality. The World Bank. Available from:

http://data.worldbank.org/indicator/SH.DYN.MORT. [Accessed May 4, 2012].

http://www.moroccousafta.com/maratglance.htm

http://www.oanda.com/currency/historical-rates/

http://www.ompic.org.ma/ompic_en_191.shtm

http://www.ompic.org.ma/ompic_en_186.shtm

http://www.ramed.ma/ServicesEnligne/APropos.html

http://www.invest.gov.ma/?lang=fr&Id=3

http://data.worldbank.org/indicator/SH.XPD.OOPC.TO.ZS?page=1

http://data.worldbank.org/indicator/NE.EXP.GNFS.ZS

SAMPLE




The World Bank (2012j). CO2 Emissions (Million Tons). The World Bank. Available from:

http://data.worldbank.org/indicator/EN.ATM.CO2E.KT. [Accessed May 7, 2012].

The World Bank (2012k). PM10 (Microgram per Cubic Meter). The World Bank. Available from:

http://data,worldbank,org/indicator/EN,ATM,PM10,MC,M3. [Accessed May 7, 2012].

The World Bank (2012l). Organic Water Pollutant Emissions (Metric Tons per Day). The World Bank.

Available from: http://data.worldbank.org/indicator/EE.BOD.TOTL.KG. [Accessed May 7, 2012].

The World Bank (2012m). Healthcare Expenditure (% of GDP). The World Bank. Available from:

http://data.worldbank.org/indicator/FI.RES.TOTL.CD/countries?page=1. [Accessed June 1, 2012].

The World Bank (2012n). Healthcare Expenditure, Public (% of total health expenditure). The World

Bank. Available from: http://data.worldbank.org/indicator/SH.XPD.PUBL. [Accessed June 1, 2012].

The World Bank (2012o). Doing Business. The World Bank. Available from:

http://www.doingbusiness.org/data/exploreeconomies/morocco. [Accessed June 1, 2012].

US Commercial Service (2005). Medical Equipment-Morocco. Available from:

http://www.buyusainfo.net/docs/x_6564383.pdf.

US Department of State (2009). 2009 Investment Climate Statement - Morocco. Available from:

http://www.state.gov/e/eb/rls/othr/ics/2009/117848.htm. [Accessed, 2012].

US Department of State (2011). 2011 Investment Climate Statement - Morocco. Available from:

http://www.state.gov/e/eb/rls/othr/ics/2011/157329.htm. [Accessed, 2012].

US Department of State (2012). Background Note: Morocco. Available from:

http://www.state.gov/r/pa/ei/bgn/5431.htm#political. [Accessed May 30, 2012].

USDA (2009). Food and Drug Safety Regulation. Available from:

http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food%20and%20Agricultural%20Import%

20Regulations%20and%20Standards%20-%20Narrative_Rabat_Morocco_7-24-2009.pdf.

Van Mourik et al (2010). Availability, price and affordability of cardiovascular medicines: A

comparison across 36 countries using WHO/HAI data. BioMed Central Ltd. BMC Cardiovascular

Disorders 2010, 10:25.

WHO (2006). Health system profile Morocco. Available from:

http://gis.emro.who.int/HealthSystemObservatory/PDF/Morroco/Full%20Profile.pdf.

WHO (2008). Constraints and Obstacles to Social Health Protection in the Maghreb: The Cases of

Algeria and Morocco. Available from: http://www.who.int/bulletin/volumes/86/11/08-053736.pdf.

WHO (2009). Disability Adjusted Life Years. World Health Organization. Available from:

http://www.who.int/healthinfo/global_burden_disease/en/. [Accessed March 25, 2012].

WHO (2011). Global Health Observatory Data Repository. World Health Organization. Available from:

http://apps.who.int/ghodata/?vid=10011. [Accessed March 27, 2012].

World Trade Organization (2003). Trade Policies and Practices by Measure. Licensing Process for

Exports and Imports. World trade Organization (2003). Available from:

http://www.google.co.in/url?sa=t&rct=j&q=adsp%20new%20drug%20morocco&source=web&cd=4&v

ed=0CFMQFjAD&url=http%3A%2F%2Fwww.wto.org%2Fenglish%2Ftratop_e%2Ftpr_e%2Fs116-

3_e.doc&ei=rM3VT9_2A4yZiAf4pYH-Ag&usg=AFQjCNFYZHb_sFaZpHYI3NfAUTgZgdegUA.


http://data,worldbank,org/indicator/EN,ATM,PM10,MC,M3

http://www.state.gov/e/eb/rls/othr/ics/2009/117848.htm

http://www.state.gov/r/pa/ei/bgn/5431.htm#political

http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food%20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-%20Narrative_Rabat_Morocco_7-24-2009.pdf

http://gain.fas.usda.gov/Recent%20GAIN%20Publications/Food%20and%20Agricultural%20Import%20Regulations%20and%20Standards%20-%20Narrative_Rabat_Morocco_7-24-2009.pdf

http://gis.emro.who.int/HealthSystemObservatory/PDF/Morroco/Full%20Profile.pdf

http://www.who.int/bulletin/volumes/86/11/08-053736.pdf

http://apps.who.int/ghodata/?vid=10011

http://www.google.co.in/url?sa=t&rct=j&q=adsp%20new%20drug%20morocco&source=web&cd=4&ved=0CFMQFjAD&url=http%3A%2F%2Fwww.wto.org%2Fenglish%2Ftratop_e%2Ftpr_e%2Fs116-3_e.doc&ei=rM3VT9_2A4yZiAf4pYH-Ag&usg=AFQjCNFYZHb_sFaZpHYI3NfAUTgZgdegUA



SAMPLE




7.3 Methodology

GlobalData‟s dedicated research and analysis teams consist of experienced professionals with advanced

statistical expertise and marketing, market research and consulting backgrounds in the pharmaceutical

industry.

GlobalData adheres to the codes of practice of the Market Research Society (www.mrs.org.uk) and the

Strategic and Competitive Intelligence Professionals (www.scip.org).

All GlobalData databases are continuously updated and revised. The following research methodology is

followed for all databases and reports.

7.3.1 Coverage

The objective of updating GlobalData‟s coverage is to ensure that it represents the most up to date vision

of the industry possible.

Changes to the industry taxonomy are built because of extensive research of company, association and

competitor sources.

Company coverage is based on three key factors: revenues, products and media

attention/innovation/market potential.

The estimated revenues of all major companies, including private and governmental, are gathered

and used to prioritize coverage.

Companies which are making the news or which are of particular interest due to their innovative

approach are prioritized.

GlobalData aims to cover all major news events and deals in the pharmaceutical industry, updated on a

daily basis.

The coverage is further streamlined and strengthened with additional inputs from GlobalData‟s expert

panel (see below).

7.3.2 Secondary Research

The research process begins with exhaustive secondary research on internal and external sources being

carried out to source qualitative and quantitative information relating to each market.

The secondary research sources that are typically referred to include, but are not limited to:

Company websites, annual reports, financial reports, broker reports, investor presentations and the

US Securities and Exchanges Commission (SEC) filings

Industry trade journals, scientific journals and other technical literature

Internal and external proprietary databases

Relevant patent and regulatory databases

National government documents, statistical databases and market reports

Procedure registries

News articles, press releases and web-casts specific to the companies operating in the market.

The country reports are largely based on secondary research and make use of reliable and authoritative

sources such as the IMF, The World Bank, OECD, WHO, UNICEF, UNStats, MHLW, NHS, and BEA,

among others.

http://www.mrs.org.uk/

http://www.scip.org/

SAMPLE




7.3.3 Forecasting

For the country reports, GlobalData uses the data available from reliable and authoritative secondary

sources to forecast the future trends for the healthcare market for the country, as well as the parameters

related to the economy and healthcare infrastructure and expenditure of the country. The trends are

further validated through the secondary sources.

7.3.4 Primary Research

GlobalData conducts hundreds of primary interviews a year with industry participants and commentators

in order to validate its data and analysis. A typical research interview fulfills the following functions:

It provides first-hand information on the market size, market trends, growth trends, competitive

landscape and outlook of a market.

It helps in validating and strengthening secondary research findings.

It develops the analysis team‟s expertise and market understanding.

Primary research involves email correspondence and telephone interviews as well as face-to-face

interviews for each market, category, segment and sub-segment across the geographies covered.

The participants who typically take part in such a process include, but are not limited to:

Industry participants: Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing/product

managers, market intelligence managers and national sales managers.

Hospital stores, pharmacies, distributors and paramedics.

Outside experts: investment bankers, valuation experts, research analysts specializing in specific

pharmaceutical markets.

Key Opinion Leaders (KOLs): Physicians and surgeons specializing in different therapeutic areas

corresponding to different kinds of pharmaceuticals.

7.3.5 Expert Panel Validation

GlobalData uses a panel of experts to cross verify its databases and forecasts.

GlobalData‟s expert panel comprises marketing managers, product specialists, international sales

managers from pharmaceutical companies; academics from research universities, KOLs from hospitals,

consultants from venture capital funds, and distributors/suppliers of pharmaceuticals and supplies.

Historic data and forecasts are relayed to GlobalData‟s expert panel for feedback and adjusted in

accordance with their feedback.

7.4 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by

any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of

the publisher, GlobalData.